Dicycloplatin can be used in cancer research; it induces cell cycle arrest, inhibits proliferation, and triggers apoptosis in prostate cancer PC3 cells and lung cancer NCI/H446 cells by causing DNA damage through activation of diphosphorylated checkpoint kinase 2 (CHK2), breast cancer 1 (BRCA1), and triphosphorylated p53.